Loading...
Market
How will Novo Nordisk's stock price react to the NAION risk study by July 31, 2024?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Stock market data from financial news and stock exchanges
Story
Harvard Study Links Ozempic, Wegovy to 6.7% Risk of Serious Eye Condition
Jul 3, 2024, 03:39 PM
A new study by Massachusetts Eye and Ear and Harvard has revealed a potential link between Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. The study, published in JAMA Ophthalmology, found that patients prescribed these drugs for diabetes or weight loss had a higher risk of developing NAION compared to those not on the medication. The risk of optic neuropathy was 6.7% for the Ozempic group and 0.8% for the control group at 36 months. This is the first report of such an association, based on a matched cohort of approximately 17,000 individuals, highlighting the need for further research to understand the safety implications of these widely used medications.
View original story
Similar markets
Yes • 50%
No • 50%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Acknowledge risk and issue warning • 25%
Deny risk and continue marketing • 25%
Initiate further studies • 25%
Discontinue affected products • 25%